Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...
1don MSN
Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
in the effort to create a vaccine. Will their partnership lead to a new model for drug development that accelerates medical innovation? Here’s Afeyan again: ...
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
Other fact-checking organizations have debunked the claim; Reuters and AFP have also fact-checked similar claims that circulated in 2022 and 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback